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Background: The African Programme for Onchocerciasis Control (APOC) was created to control onchocerciasis as a
public health problem in 20 African countries. Its main strategy is community directed treatment with ivermectin. In
order to identify all high risk areas where ivermectin treatment was needed, APOC used Rapid Epidemiological
Mapping of Onchocerciasis (REMO). REMO has now been virtually completed and we report the results in two
articles. The present article reports the mapping of high risk areas where onchocerciasis was a public health
problem. The companion article reports the results of a geostatistical analysis of the REMO data to map endemicity
levels and estimate the number infected.
Methods: REMO consists of three stages: exclusion of areas that are unsuitable for the vector, selection of sample
villages to be surveyed in each river basin, and examination of 30 to 50 adults for the presence of palpable
onchocercal nodules in each selected village. The survey results and other relevant information were processed in a
geographical information system. A panel of experts interpreted the data taking the river-based sampling into
account and delineated high risk areas where the prevalence of nodules is greater than 20%.
Results: Unsuitable areas were identified in eight countries. In the remaining areas surveys were done in a total of
14,473 sample villages in which more than half a million people were examined. High-risk areas were identified in
18 APOC countries, ranging from small isolated foci to a vast contiguous endemic area of 2 million km2 running
across seven countries. In five countries the high risk area covered more than 48% of the total surface area, and
31% to 48% of the population. It is estimated that 86 million people live in high risk areas in the APOC countries.
Conclusions: The REMO maps have played a significant role in onchocerciasis control in the 20 APOC countries. All
high-risk areas where onchocerciasis used to be a serious public health problem have been clearly delineated. This
led to the creation of community-directed treatment projects that by 2012 were providing annual ivermectin
treatment to over 80 million people.
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Onchocerciasis, or river blindness, is caused by infection
by the filarial worm Onchocerca volvulus which is
transmitted by female black flies of the genus Simulium.
Onchocerciasis used to be endemic in some 30 countries
in Africa where over 99% of all cases in the world were
found [1]. In most of these countries, onchocerciasis was
a severe public health problem, responsible for blindness
and visual impairment, debilitating skin disease and
relentless itching in millions of people, and the disease
had serious socio-economic consequences, including
depopulation of fertile river valleys and reduced productiv-
ity of affected persons [1-3]. Since 1975 there have been
large-scale efforts to control the disease as both a
public health problem and obstacle to socio-economic
development. The Onchocerciasis Control Programme
in West Africa (OCP) has successfully controlled
onchocerciasis by vector control in the savanna belt
of nine West African countries [4]. However, in the
remaining endemic areas in Africa, where the large
majority of onchocerciasis cases lived, vector control
was not considered feasible or cost-effective and no
chemotherapy existed that was suitable for onchocerciasis
control [5]. The registration of ivermectin for the treatment
of human onchocerciasis in 1987 was therefore a major
breakthrough. The evidence from community trials that
annual ivermectin treatment could effectively control the
disease and the commitment by the manufacturer to
donate ivermectin free of charge for as long as needed led
to a rapid expansion of onchocerciasis control activities
[6,7]. An international coalition of Non-Governmental
Development Organizations (NGDOs) spearheaded
ivermectin distribution efforts [8] and in 1995 the African
Programme for Onchocerciasis Control (APOC; see
Figure 1) was created with the mandate to support
the establishment of community directed treatment with
ivermectin (CDTi) in all remaining areas in Africa where
onchocerciasis was a public health problem [5].
One of the first challenges for APOC was to determine
exactly where onchocerciasis was a public health problem
and CDTi was a priority. Historical information did exist
on the distribution of onchocerciasis in the 20 APOC
countries in the form of reports on prevalence surveys in
single or clusters of villages [9-30], reviews of the
available information on the distribution of onchocerciasis
in different countries [31-56] and attempts by WHO
to interpret all this information and draw maps of the
approximate distribution of onchocerciasis in Africa
[1,57,58]. However, for most areas the available information
was either incomplete or not accurate and reliable enough
for targeting ivermectin treatment programmes [5,59].
There was, therefore, an urgent need for comprehensive
mapping of the geographic distribution of onchocerciasis in
all potentially endemic countries in Africa outside the OCP[60]. This was a vast area of some 14 million km2 and it
would have been extremely difficult to determine the
distribution of onchocerciasis throughout this area
using the mapping and survey methods that were
current at that time [61]. The distribution of different
vector species and the location of the breeding sites
were not known, while the principal diagnostic tool in use
was a parasitological method based on the microscopic
examination of skin biopsies; a time-consuming and
invasive method. In response to these problems, a
rapid assessment method for the Rapid Epidemiological
Mapping of Onchocerciasis (REMO) was developed in
1993 and successfully tested at scale in Cameroon and
Nigeria [62].
The geographic distribution of onchocerciasis is largely
determined by the ecology and behavior of the vector
[63]. Simulium vector flies breed in fast flowing, well
oxygenated rivers and streams with adequate nutrients.
The adult female flies disperse mainly along the river
and their flight range rarely exceeds more than 15 km
away from the river when seeking a blood meal [63-65].
Hence, the highest prevalence rates of onchocerciasis
infection are almost invariably observed among villages
located close to rivers with Simulium breeding sites.
REMO uses this knowledge to identify potentially endemic
areas and to select sample villages to be surveyed taking
the ecology and the spatial behaviour of Simulium vectors
into account.
The selected sample villages are surveyed using a
non-invasive rapid assessment method to estimate their
level of onchocerciasis endemicity. In each selected village
a sample of adults is examined for the presence of
palpable subcutaneous onchocercal nodules and the
prevalence of nodules is calculated. Previous studies
had shown that the severity of onchocercal disease in the
community, and thus its public health importance, is
related to the level of onchocerciasis endemicity as also
reflected in the prevalence of nodules [2,66,67]. Based on
available data on this relationship, an expert committee
recommended in the early 1990s that, in order to control
onchocerciasis as a public health problem, ivermectin
treatment should be provided to all high risk communities
where the prevalence of onchocercal nodules in adults
was greater than 20% [68].
The development of REMO came just in time for
APOC, which swiftly adopted this rapid assessment method
and supported its large-scale application for mapping
onchocerciasis in all APOC countries in order to identify
priority areas for CDTi [59]. REMO thus became an essen-
tial first step in the planning and implementation of national
onchocerciasis control programs supported by APOC.
Large scale application of REMO started in 1996, and has
since been applied in phase with the expansion of CDTi to
cover all potentially endemic areas in APOC countries.
Figure 1 Participating countries in the African Programme for Onchocerciasis Control (APOC).
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20 APOC countries have been mapped for onchocercia-
sis through REMO. Some partial results have been
reported previously [59,69-73]. We report the complete
results of the REMO surveys and the spatial analysis of
the REMO data in two articles. The present article
summarises the REMO surveys and shows the results of
an expert analysis to delineate high-risk areas where
onchocerciasis was a major public health problem and
where ivermectin treatment was a priority for onchocerciasiscontrol. These REMO maps of high risk areas have
been the basis for the delineation of the CDTi projects
that by 2011 were treating over 80 million people in the
APOC countries [74]. In a companion paper we report
the results of a geostatistical analysis of the REMO data
using a methodology that was recently introduced in
APOC [75] and that has allowed the mapping of
onchocerciasis endemicity levels and the estimation of
the number of people that would have been infected
in the absence of control [76].
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REMO methodology
The spatial epidemiology of onchocerciasis, or river
blindness, is closely related to the distribution of local
river systems, their suitability for simulium breeding and
the flight range of the vector when seeking a blood meal.
REMO is based on this knowledge and consists of three
stages [77]:
1) The division of the area that needs to be mapped
into biogeographic zones that are reasonably
uniform with regard to their potential for
onchocerciasis and that cover the watersheds of the
main local drainage systems. Areas that are known
to be unsuitable for the vector for ecological reasons
(absence of fast flowing water, high altitude, etc) and
uninhabited national parks are excluded at this stage.
2) The selection of a sample of villages to be surveyed
in order to determine whether onchocerciasis is
present or not and, if present, to give a rough
indication of the distribution and severity of
onchocerciasis in the zone. This sampling uses the
available information on the local river system and
involves two steps for each river basin:
a) Selection of villages at high risk locations. These
are villages that are located in places where the
risk of onchocerciasis is likely to be highest, i.e.
close to the river bank, close to rapids and
without other human settlements between them
and the river. At least one high risk village is to
be sampled every 30 to 50 km along the river and
each major tributary.
b) Selection of secondary villages. For each high risk
village, a related secondary village is selected
which is located at least 10 km away from the
river and the likely source of vectors.
3) Rapid epidemiological assessment (REA) surveys in
the selected villages. A sample of 30-50 adults aged
20 years or more who are resident in the village
for at least 10 years are examined for the presence
of nodules, and the percentage of adults with
palpable onchocercal nodules is calculated. The
geographic coordinates of each village are
collected using a hand-held Global Positioning
System (GPS) receiver in a central location in
the village.
The full details of the REMO methodology are provided
in the WHO Manual for Rapid Epidemiological Mapping
of Onchocerciasis [77].
REMO implementation in APOC countries
The implementation of REMO was the responsibility of the
Ministry of Health of each APOC country in collaborationwith its partners in onchocerciasis control and with tech-
nical and financial support from APOC [59]. Each APOC
country has a National Onchocerciasis Task Force (NOTF)
that brings the various partners together in order to coord-
inate the onchocerciasis control activities in the country.
The manager of the NOTF is the responsible officer
for onchocerciasis control in the Ministry of Health. The
NOTF of each country submitted to APOC a plan of ac-
tion and budget for REMO. Upon approval this plan,
APOC provided the agreed funding and external experts
to train and support national teams with the
implementation of REMO. Some REMO activities were
funded and/or undertaken by NGDOs, but always under
the auspices of the Ministry of Health and following the
WHO guidelines for REMO surveys.
During the first years of APOC, priority for REMO
was given to those areas where local partners were ready
to support CDTi. Nigeria was one of the first and largest
countries to implement REMO. Though all REMO
surveys were reportedly undertaken according to the
standard procedures as described in the REMO manual,
there was no direct APOC involvement in the actual
survey activities in the field during the first years. The
main system of quality control was the review of the
survey results by the Technical Consultative Committee
(TCC) of APOC, a group of experts who technically
advise the programme. Where TCC had reservations
about survey results, the REMO surveys were repeated
with participation of external experts. In case the results
of these validation surveys deviated from the initial
findings (which did happen in a few cases [69]), the
original data were replaced by the validation data. During
the first years, there was incomplete standardization of
reporting: all REMO teams did report for each surveyed
village the critical survey data, i.e. the village coordinates
and the percentage of examined adults with nodules, but
other information such as the date of survey or the
number of adults examined were not always included in
the reports to APOC. Furthermore, during the first years
handheld GPS receivers were not yet widely available
and village coordinates were often obtained using
local maps. However, after this first period, all REMO
surveys were implemented using handheld GPS receivers
provided by APOC and with the participation of ex-
ternal experts to ensure standardized quality control
and reporting.
Analysis of REMO data
The analysis of the REMO data was undertaken using
two analytical approaches: an expert analysis using
the original REMO analytical methodology for which
the results are reported in this article, and a geosta-
tistical analysis which is described in the companion
article [76].
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All relevant geographic information was processed in a
geographic information system. Initially Atlas GIS was used
but since 2010 all geographic information was processed
and analysed using ArcGIS 10 (ESRI Inc., Redlands, USA)
including the analysis reported in his article.
The geographic information used for the analysis
included:
– National and administrative boundaries, rivers and
lakes, national parks, main roads, villages and urban
settlements (source WHO HealthMapper http://
health-mapper-release-5.software.informer.com).
– Topography and relief (source ESRI http://services.
arcgisonline.com/ArcGIS/rest/services/
World_Shaded_Relief/MapServer)
– Population density at 30 arc seconds resolution
(source LandScan http://www.ornl.gov/sci/landscan/
index.shtml)
– Areas that are unsuitable for onchocerciasis as
defined during the first REMO phase (see above)
– Geographic coordinates of all surveyed villages and
for each surveyed village the percentage of examined
persons who had palpable nodules, referred to as the
“prevalence of nodules” or “nodule prevalence” in
this article.
Expert analysis
The original analytical approach based on expert analysis
is described in detail in the REMO manual and the
Guidelines for Analysis of REMO data [77,78]. Using the
GIS a group of onchocerciasis experts reviewed and
interpreted the REMO survey data while taking the
original river-based sampling into account. The boundaries
of the biogeographic zones and river basins that were used
in the sampling were displayed on a map, together with
spatial information on rivers and their affluents, lakes,
national parks, elevation, landscape, population and
administrative boundaries. For each surveyed village, the
nodule prevalence was displayed as a pie chart at the
location defined by its GPS coordinates. Using these maps,
the experts tried to delineate the areas where the preva-
lence of nodules is greater than 20%, and where ivermectin
treatment is therefore indicated (High Risk areas), and the
areas where the prevalence of nodules is below the 20%
threshold, including areas where the prevalence of nodules
was zero, and where ivermectin treatment is not needed or
not a priority (Low Risk areas).
Figure 2 gives an example of the expert analysis
process for a surveyed area north of the town of Douala
in Cameroon. The landscape in this area is very variable.
Just around Douala there is a river delta between 5 m
and 30 m above sea level. This low level area is surrounded
by hills between 250 and 500 m high, a few mountain peaksin the East and North up to 1000 to 2000 m high, and
Mount Cameroon in the south-east which peaks at 4040 m
above sea level and were the upper reaches of the mountain
are unsuitable for onchocerciasis vectors because of the
high altitude. A large number of REMO surveys have been
done in this area, showing very high levels of onchocerciasis
endemicity in the hilly areas where most surveyed villages
had a nodule prevalence > 60%, and very low endemicity in
the lower reaches of the river delta. The likely explanation
for this pattern is that in the hilly and mountainous areas
there are many streams with rapidly flowing water that
provide ample breeding sites for Simulium vectors, while
there are no good conditions for vector breeding in the
more slowly flowing waters in the low level river delta.
The locally available entomological data supported this
explanation. Having arrived at this basic understanding of
the local epidemiology of onchocerciasis, the experts
proceeded with classifying hilly areas with high nodule
prevalence data as high risk areas, and the river delta area
just north of Douala where the prevalence of nodules
ranged between 0% and 17% as a low risk area. The
boundary between these two risk areas was then drawn
taking the geographic information on rivers, altitude
and nodule prevalence into account. Where the nodule
prevalence data were mixed, e.g. to the east where there is
a borderline area with three surveyed villages with a
nodule prevalence > 40% and four villages with a
prevalence between 0% and 10%, the area was classified as
high risk given the presence of several villages with a high
prevalence of nodules.
A similar process was applied in the analysis of the
REMO survey data for all other surveyed areas in the
APOC countries. The classifications of all these surveyed
areas was reviewed in detail in March 2010 by an APOC
panel of 10 onchocerciasis epidemiologists and ento-
mologists who refined some of the classifications and
endorsed the overall map. A final round of review
was undertaken in January 2013 by the staff of the
epidemiological evaluation unit of APOC following
some additional classifications and refinements, notably
for Ethiopia where another round of REMO surveys were
undertaken in 86 villages in 2012.
Estimation of the population at high risk
The population at high risk is here defined as the rural
population living in the high risk areas identified in the
expert analysis. Onchocerciasis is not normally transmit-
ted in urban settlements and urban populations that are
not engaged in rural activities are excluded from estimates
of the population at high risk. This exclusion criterion is
not just a function of population size but depends on
an assessment of the degree of urbanisation and the
corresponding lack of exposure to the vector. Based
on local assessments, each CDTi project decides which
Figure 2 Expert analysis of REMO data: examples for Litoral and South-West provinces in Cameroon. Panel A: Results of REMO surveys.
Panel B: Delineation of high and low risk areas.
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of onchocerciasis. We have, therefore, used an estimate of
the density of the population at risk that is based on
reported data for the target population for ivermectin
treatment in ongoing CDTi projects. For each country the
average population density in onchocerciasis endemic
areas was estimated by dividing the reported target
population in CDTi projects by the surface area for
these projects. The total population in high risk areaswas subsequently obtained by multiplying for each
country the high risk surface area and the average
population density for onchocerciasis endemic areas
in that country.
Ethical considerations
REMO is the first step in national planning for
onchocerciasis control and in each APOC country it was
undertaken under the auspices and ethical responsibility
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undertaken according to the WHO recommended
methodology that was reviewed and approved by the
Technical Consultative Committee of APOC and the
Ministries of Health of the APOC countries. All REMO
implementation plans were reviewed and cleared by the
respective Ministry of Health and TCC. A major ethical
consideration was the need to have reliable information
on the geographic distribution of onchocerciasis to ensure
that all populations at high risk of onchocerciasis would
receive ivermectin treatment. In each village, the import-
ance of the survey for possible future ivermectin treatment
in the village was explained and village members were
encouraged to participate in the examination. Participation
was not compulsory and those who were requested to
participate but decided not to come to the examination
point, were not followed up. The examination itself was a
simple non-invasive examination undertaken in a secluded
location in the village.
Results
Unsuitable and uninhabited areas
The first step in the implementation of REMO in each
country involved the identification of possible areas that
are unsuitable for onchocerciasis transmission, and where,
therefore, no further surveys were required. Large unsuit-
able areas were identified in eight countries: Central
African Republic, Chad, Congo, Ethiopia, Kenya, Sudan,
South Sudan and Tanzania. They included vast arid areas
in Chad, Sudan and Ethiopia and swamps in Congo and
South Sudan where the lack of fast flowing water made
these areas unsuitable for Simulium breeding. In Sudan the
area along the Blue Nile was also classified as unsuitable
for onchocerciasis based on reports of previous surveys
that found no cases of human onchocerciasis in the area
even though the vector was sometimes present at very low
densities [31]. Most of Kenya was classified as unsuitable
on the basis of extensive previous entomological work that
had shown that the only vector in the country was S.naevi
and that its distribution was restricted to Nyanza province
in the West of the country [25,39]. The dry central plateau
of Tanzania was classified as being too dry to be suitable
for Simulium breeding.
National parks were also excluded from further
analysis. Population density was not used as an exclusion
criterion. However, for areas where, according to the
LandScan database, the population density is extremely
low (<1 person per km2) this information is displayed on
the maps.
REMO surveys
The database used for the analysis consisted of REMO
data for 14,341 villages where pre-control surveys
were undertaken between 1995 and 2012. In addition,pre-control data were made available to APOC for
132 villages from Nigeria (101 villages), Cameroon
(18 villages) and Tanzania (13 villages) where skin
snip surveys had been done. For the purpose of analysis,
the prevalence of microfilaria for these 132 villages was
converted into the prevalence of nodules using the relation-
ship between these two indicators described in a recent
publication [79]. The final database consisted of survey data
for 14,473 villages in which more than half a million people
were examined for onchocercal nodules (Table 1).
Figure 3 shows the locations of the surveyed villages
and of the classified area, i.e. the area that the experts
classified as having high or low risk based on the survey
results. The sampling density of survey villages varied
between countries as the national onchocerciasis control
programmes in several countries decided to survey
villages at shorter distances than the recommended
distance of 30 to 50 km between sample villages [77].
The reasons for these decisions included the need for
very detailed onchocerciasis endemicity maps in areas
that bordered zones where loiasis was highly endemic
and where there was therefore a high risk of severe
adverse reactions to ivermectin treatment (e.g. Bas Congo
in the Democratic Republic of Congo [69]). Other reasons
were highly variable relief in some areas with significant
local variations in elevation (Rwanda, Burundi, Ethiopia),
the desire by some national programmes to have more
detailed information (e.g. Malawi), or a decision by a local
CDTi project to do REMO surveys in all villages in
its catchment area in order to collect a complete set of
baseline data for onchocerciasis control (e.g. Ouham-Pendé
Prefecture in the Central African Republic). In none
of the classified areas did the average distance between
neighbouring sample villages exceed the recommended
distance of 30 to 50 km.
In 92% of the surveyed villages, the recommended
number of 30 to 50 adults was examined for palpable
nodules. In 2.2% of the villages, more than 50 adults
were examined and in 5.8% of villages the number of
examined adult males was less than 30. In some areas
the selected villages were often too small to reach the
recommended minimum of 30 adult males for examination.
This was notably the case in Gabon where the threshold of
30 adults could not be reached in 62% of the selected
villages and where on average 28 adults were examined per
village (Table 1), and in parts of Mozambique and Rwanda
where some 25% of selected villages were too small to
obtain a sample of at least 30 adult males. In the original
sample there were 60 very small settlements with less
than 12 adult males examined and these were excluded
from the analysis.
Of the total of 576,368 persons examined, 22.0% had
palpable onchocercal nodules. The prevalence of palpable
onchocercal nodules varied significantly between villages
Table 1 Summary of the REMO surveys undertaken in the 20 APOC countries
Country Villages surveyed # of persons examined Examined persons with
palpable nodules
Prevalence of nodules per village (%)
Total per village Total Percentage Minimum Median Maximum
Angola 763 25,758 34 2,491 9.7 0.0 5.3 63.3
Burundi 150 6,053 40 501 8.3 0.0 3.3 83.3
Cameroun 817 30,179 37 8,625 28.6 0.0 20.0 100.0
Central African Republic 1,078 34,984 32 15,952 45.6 0.0 50.0 100.0
Chad 483 15,795 33 2,348 14.9 0.0 6.7 96.7
Congo 384 13,853 36 1,352 9.8 0.0 3.3 71.4
Democratic Republic of Congo 4,389 170,799 39 53,501 31.3 0.0 23.3 100.0
Equatorial Guinea 209 7,751 37 1,527 19.7 0.0 11.8 73.3
Ethiopia 885 30,355 34 5,458 18.0 0.0 14.6 81.5
Gabon 59 1,633 28 29 1.8 0.0 0.0 11.8
Kenya 94 3,822 41 8 0.2 0.0 0.0 4.8
Liberia 89 4,208 47 798 19.0 0.0 20.0 35.0
Malawi 291 13,122 45 543 4.1 0.0 0.0 36.0
Mozambique 289 10,325 36 99 1.0 0.0 0.0 16.2
Nigeria 2,716 127,459 47 21,165 16.6 0.0 12.0 96.0
Rwanda 89 3,126 35 20 0.6 0.0 0.0 6.0
South Sudan 473 16,501 35 2,211 13.4 0.0 10.0 93.3
Sudan 427 21,330 50 175 0.8 0.0 0.0 23.3
Tanzania 331 20,592 62 5,035 24.5 0.0 20.8 100.0
Uganda 457 18,723 41 4,772 25.5 0.0 20.0 100.0
Total 14,473 576,368 40 126,612 22.0 0.0 14.0 100.0
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where the prevalence was zero. The maximum prevalence
per village varied from 4.8% in Kenya to 100% in
five countries (Cameroon, Central African Republic,
Democratic Republic of the Congo, Tanzania and Uganda).
For Gabon, Kenya, Mozambique and Rwanda the highest
prevalence of nodules per village was between 4.8% and
16.2%, i.e. everywhere below the high risk threshold of
20%. The highest median prevalence of 50% was observed
in the Central African Republic, followed by Cameroon,
Democratic Republic of Congo, Tanzania and Uganda with
a median prevalence of palpable onchocercal nodules per
village between 20% and 23%.
High risk areas
The main results of the expert analysis are given in
Figure 4 which shows the areas classified as high risk
and low risk for onchocerciasis in the 20 APOC
countries. There is a vast, contiguous high risk area in the
centre of Africa covering most of the Democratic Republic
of Congo, South Sudan and the Central African Republic,
extending in the South into Angola, in the East into
Uganda and in the West into South Chad, Cameroon and
Nigeria. Large high-risk areas are also found in Angola,Congo, Tanzania, Ethiopia and Liberia, and smaller but
densely populated high risk areas in Malawi and Burundi.
Cross-border foci are common and found in all APOC
countries with high risk areas. Kenya, Rwanda, the
mainland of Equatorial Guinea, as well as nearly all
of Gabon, Mozambique and Sudan were classified as
low risk. In the Abu Hamed focus in Sudan the
prevalence of nodules was just below 20%, but in this area
hyper-reactive onchodermatitis or Sowda is common,
and the 20% prevalence may not be an adequate
threshold for the public health importance of the disease
in this focus.
There are some areas that could not be classified
because no REMO surveys had been done. However,
as shown in the map, many of these unclassified areas
had a very low population density of <1 person per
km2. Only for a few more densely populated areas
there is no survey data available, notably in Tanzania,
Angola and the Democratic Republic of Congo. For
some unsurveyed but populated areas the surrounding
zones were all classified as high risk while the environment
was similar in terms of climate, hydrology, vegetation and
altitude. Such areas were therefore classified as “assumed
high risk” pending future validation by additional
Figure 3 Location of the 14,473 surveyed villages in the 20 APOC countries.
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some unsurveyed populated areas were classified as
“assumed low risk” if all the surrounding areas were
consistently classified as low risk and the environment
was similar between those areas.
The total surface of the areas classified as high risk is
3.3 million km2 (Table 2), representing 24% of the
surface of the 20 APOC countries. In Cameroon, the
Central African Republic, the Democratic Republic of
Congo and Liberia more than half the surface of the
country was classified as high risk for onchocerciasis,while in South Sudan and Nigeria the high risk area
represents 49% and 43% of the country respectively.
In Gabon and Mozambique only 0.3% of the surface
was classified as a high risk area. In both cases, it
concerned a narrow border area where no REMO
surveys were done within the country itself but where
the presence of a large endemic focus on the other side of
the border in the neighbouring country suggests that there
may be also some hyperendemic villages on the banks of
the border river within Gabon and Mozambique. Except
for those narrow border areas, the REMO data for
Figure 4 High Risk and Low Risk areas in the APOC countries – results of the expert analysis.
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any high risk areas.Population of high risk areas
The total population of the high risk areas is estimated
at 86 million for the year 2011, corresponding to some
15% of the total population of the 20 APOC countries.
Most of the high risk area population comes from
Nigeria (26 million) and the Democratic Republic of
Congo (28 million). In Cameroon, the Central African
Republic, the Democratic Republic of Congo and Liberia,the population of high risk areas represents some 31 to
48% of the total population of the country.Discussion
APOC’s first major task was to determine where
onchocerciasis was a public health problem and where
ivermectin treatment should therefore be targeted. It was
a daunting challenge because of the vast area in the 20
APOC countries where onchocerciasis was potentially
endemic. Only by using the rapid assessment method
REMO, APOC was able to map the high risk areas within
















Angola 1,247 19,082 3.8 262.3 21.0% 985 5.2%
Burundi 28 8,383 341.0 3.4 12.3% 1,166 13.9%
Cameroon 475 19,599 24.2 249.5 52.5% 6,027 30.8%
CAR 623 4,401 5.2 328.1 52.7% 1,693 38.5%
Chad 1,284 11,227 21.6 93.7 7.3% 2,024 18.0%
Congo 342 4,043 34.8 20.9 6.1% 727 18.0%
DRC 2,345 65,966 22.1 1,247.3 53.2% 27,573 41.8%
Eq. Guinea 28 700 22.0 1.1 3.8% 87 12.4%
Ethiopia 1,104 82,950 46.7 177.1 16.0% 8,271 10.0%
Gabon† 268 1,505 3.8 0.7 0.3% 3 0.2%
Kenya 584 40,513 NA 0.0 0.0% 0 0.0%
Liberia 96 3,994 30.2 63.1 65.5% 1,904 47.7%
Malawi 118 14,901 237.4 7.2 6.1% 1,713 11.5%
Mozambique† 799 23,391 18.0 2.6 0.3% 46 0.2%
Nigeria 924 158,423 65.3 400.2 43.3% 26,120 16.5%
Rwanda 25 10,624 NA 0.0 0.0% 0 0.0%
South Sudan 644 10,693 13.8 312.5 48.5% 4,313 40.3%
Sudan 1,861 35,048 14.6 0.6 0.0% 9 0.0%
Tanzania 947 44,841 19.4 91.9 9.7% 1,783 4.0%
Uganda 242 33,425 56.4 25.5 10.6% 1,437 4.3%
Total 13,986 593,709 27.1 3,288 23.5% 85,881 14.5%
*Source: http://wdi.worldbank.org/table/1.1.
**Source: http://esa.un.org/wpp/Excel-Data/population.htm.
†Population estimated using LandScan data for the high risk areas in the country.
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launched without significant delays. However, even though
REMO is a rapid assessment method, its implementation
remained a major effort in which more than 14,000
villages were surveyed and over half a million people
examined for the presence of palpable nodules. With
the exception of a few small areas, REMO has now
been completed in all APOC countries. A comprehensive
map of the geographic distribution of onchocerciasis in
the 20 APOC countries has been produced which clearly
delineates the high risk areas where ivermectin treatment
is a priority.
High risk areas were identified in all APOC countries
except Kenya and Rwanda. They ranged from small,
isolated onchocerciasis foci (e.g. the island of Bioko
in Equatorial Guinea) to a vast contiguous endemic
area of more than 2 million km2 that runs across
seven countries. In five countries (Cameroon, Central
African Republic, the Democratic Republic of Congo,
Liberia and South Sudan) the high risk area covers
more than 49% of the total surface area of the country,
and between 31% and 49% of the total population. Anestimated 86 million people (2011 estimate) live in high
risk areas in the 18 APOC countries, with the majority
living in the Democratic Republic of Congo (28 million)
and Nigeria (26 million).
In Kenya and Rwanda there were no areas classified as
high risk. In Kenya, only 8 persons out of 3822 examined
(0.2%) had palpable nodules and given that nodule
palpation is not 100% specific [79], these results appear to
confirm the previous conclusion that onchocerciasis has
been eliminated from Kenya [1]. In Rwanda the overall
nodule rate was also extremely low, suggesting that the
country is non-endemic for onchocerciasis.
The high risk maps confirmed that the REMO surveys
were very necessary. Several of the newly identified high
risk areas were previously not even reported to have
onchocerciasis [1], e.g. five of the six high-risk areas in
Angola, the high risk areas in the north-west and
south-east of the Democratic Republic of Congo, the
high risk areas in the extreme north of Nigeria and
in the extreme south of Cameroon, and the extent of
the high-risk zone in south Tanzania. Furthermore,
for most areas that were previously thought to be
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insufficient to assess the level of endemicity and thus
the importance of the disease as a public health problem.
The REMO data clarified where the disease was a severe
public health problem and where ivermectin treatment
was a priority, thus providing the critical information
needed for launching CDTi in the APOC countries.
REMO has limitations that should be taken into
account when interpreting the risk maps. The first
relates to the use of onchocercal nodule palpation as an
indicator of onchocerciasis infection. Onchocercal nodule
palpation is subject to observer variation, and although
APOC has provided standard training in nodule palpation
to all examiners, this is unlikely to have eliminated all
observer variation between the many examiners in the
different countries. Secondly, the prevalence of nodules is
only a proxy for the risk of onchocercal disease, and the
prevalence of 20% palpable nodules only an approximate
threshold for the endemicity level where the risk of severe
onchocercal complications becomes significant. The
differentiation between high and low risk areas is based
on previous work which has shown that onchocercal
blindness is rare when the prevalence of microfilaria is
below 35% (corresponding to a nodule prevalence of about
20%), but that the risk of blindness increases with the
prevalence of microfilaria, and becomes very severe when
the prevalence of microfilaria exceeds 60% (or 40% nodule
prevalence). Given that there is no sharp cut off point for
the risk of onchocercal disease and taking into account
the small average sample size of 40 adults examined per
village, the experts tended to be cautious when the preva-
lence of nodules was around 20% and classified such areas
as requiring ivermectin treatment.
There was significant variation in village sampling
density between countries. Some countries applied the
minimum of at least one sample village every 30-50 km
along the main rivers and affluents, as recommended in
the REMO manual. Other countries and some CDTi
projects selected REMO villages at much shorter dis-
tances. However, in none of the surveyed areas did the
average distance between neighbouring sample villages
exceed the recommended distance of 30 to 50 km. There
was limited variation in the number of adults examined
per village, and in 92% of the sample villages the recom-
mended number of 30 to 50 adults was examined for
palpable nodules. Only in 5.8% of the villages was the
number of examined adults less than 30, and the reason
was usually that the selected villages were too small to
reach the required number of 30 adults who were willing
to participate in the examination. This was notably the
case for sample villages throughout Gabon and in parts
of Mozambique and Rwanda.
Although the process and criteria used in the expert
analysis are defined in the REMO manual, there remainsa substantial subjective element in the classification of
risk areas using the expert approach. For many river
basins the risk pattern was very clear, e.g. when the
prevalence for all surveyed villages was greater than 20%
and the whole basin was classified as a high risk area, or
when all prevalence rates were near zero and the whole
basin is classified as low risk. However, for other river
basins, the results were more variable making it some-
times very difficult to draw the boundary between areas
where the prevalence was above or below the 20%
threshold. In the original REMO guidelines, it was pro-
posed to undertake additional surveys in areas where the
epidemiological pattern was not sufficiently clear in
order to improve the classification. However, additional
surveys did not prove a solution in borderline areas
where the prevalence of onchocercal nodules fluctuates
around 20%. The experts tended to classify such areas as
high risk to ensure that subpopulations at high risk
onchocerciasis were not denied ivermectin treatment.
Hence, the expert analysis had a tendency to overestimate
high risk areas.
The reliability of the estimates of the population at
high risk depends on the population density estimates
used. We estimated this population density by the average
population density in the CDTi projects in each country.
This provides, in our opinion, the most reliable estimate
of the density of the population at risk in onchocerciasis
endemic areas as it excludes urban populations that are
not considered to be at risk. However, these estimates are
based on reported population data for CDTi projects.
These reported data may not always be reliable, especially
during the first years of a CDTi project when it is not yet
covering all villages in the project area or during later
years when community directed distributors (CDD)
sometimes only report the population eligible for treat-
ment rather than the total population in the village. In
both cases the effect would have been underestimation of
the population at high risk.
Conclusions
The REMO maps have played a significant role in
onchocerciasis control in the APOC countries. The clear
delineation of high risk areas has led to the creation of
more than 100 CDTi projects that by 2012 were cover-
ing a total population of 107 million people and treating
over 80 million of them who were eligible for treatment
[80]. By the year 2013, CDTi projects were covering
nearly all high risk areas in the APOC countries, thus
ensuring the control of the disease as a public health
problem and preventing 2 million Disability Adjusted
Life Years (DALYs) per year [81,82]. The main exception
was the Democratic Republic of Congo where the imple-
mentation of CDTi has been delayed because of civil un-
rest. However, in this country the coverage of CDTi is now
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where the priority areas for treatment are located.
The large scale application of REMO has provided an
evidence-based map of priority areas for ivermectin treat-
ment for onchocerciasis in 20 African countries. The map-
ping has evolved in synchrony with the progression of
onchocerciasis control, first providing detailed high risk
maps for early uptake countries and subsequently map-
ping high risk areas in other APOC countries to guide
their national CDTi planning. The final result is a detailed
epidemiological map of direct operational relevance for
onchocerciasis control that is unique among neglected
tropical diseases. This rapid, evidence-based delineation of
target areas for intervention is often quoted as one of the
main reasons for the success of the African Programme
for Onchocerciasis Control [81,83].
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